Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemophilia A With Inhibitors Clear all
Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 3:57 PM EDT
Completed No phase listed Observational

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027
View directory record Official record
Conditions
Hemophilia A
Interventions
FVIII concentrate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
13
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

NCT05306418
View directory record Official record
Conditions
Haemophilia A With or Without Inhibitors
Interventions
Mim8
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 22, 2026, 3:57 PM EDT
Completed No phase listed Observational Results available

PROPACT: Retrospective Prophylaxis Patient Case Collection

NCT00882778
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

NCT04083781
View directory record Official record
Conditions
Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

NCT02020369
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
12 Years to 75 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

NCT04205175
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Feiba
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
BAY86-6150, eptacog alfa [activated]
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 62 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Sacramento, California • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

NCT01757405
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Recombinant Factor VIIa BI (rFVIIa BI)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Not applicable Interventional

International Immune Tolerance Study

NCT00212472
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
Factor VIII concentrates, Low-dose treatment, High-dose treatment
Drug · Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
Up to 7 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2009 · Synced Jul 22, 2026, 3:57 PM EDT
Not listed Phase 2 Interventional

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

NCT01105546
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
recombinant activated factor VII
Drug
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Other
Eligibility
Up to 8 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, rFVIIa, aPCC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

NCT02448680
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation FVIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
activated prothrombin complex concentrate (FEIBA)
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
24 Months and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 22, 2026, 3:57 PM EDT
Completed No phase listed Observational

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

NCT01830712
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

NCT01051076
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
VWF/FVIII concentrates
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Phase 2 Interventional Results available

Alphanate in Immune Tolerance Induction Therapy

NCT03095287
View directory record Official record
Conditions
Hemophilia A, Congenital
Interventions
Alphanate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

NCT03154437
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Phase 3 Interventional Results available

Early Prophylaxis Immunologic Challenge (EPIC) Study

NCT01376700
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 1 Year · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

NCT00108758
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 3:57 PM EDT